Molecule of the month. Paliperidone.
D017109:Akathisia, Drug-Induced / Q000209:etiology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001007:Anxiety / Q000139:chemically induced; D017326:Clinical Trials, Phase III as Topic; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D015394:Molecular Structure; D000068882:Paliperidone Palmitate; D011743:Pyrimidines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013607:Tablets
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D007555:Isoxazoles; D011743:Pyrimidines; D013607:Tablets; D000068882:Paliperidone Palmitate